Stock OPTIMER PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Optimer Pharmaceuticals, Inc.

Equities

US68401H1041

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Optimer Pharmaceuticals, Inc.

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Optimer Pharmaceuticals, Inc. : Pre-Market Analysis: Inovio Pharmaceuticals Inc., Sequenom Inc., and Optimer Pharmaceuticals Inc.
PR
Optimer Pharmaceuticals, Inc. : Today's Research: Inovio Pharmaceuticals Inc., Onyx Pharmaceuticals Inc., Sequenom Inc. and Optimer Pharmaceuticals Inc.
PR
Optimer Pharmaceuticals, Inc. : Laboratory Permits, Pending FDA Approvals, Clinical Study Presentations, and Financial Results Release - Research Report on Illumina, Theravance, Acorda, Synta, and Optimer
PR
Optimer Pharmaceuticals, Inc. : Ryan & Maniskas, LLP Announces Investigation of Optimer Pharmaceuticals, Inc.
PR
Optimer Pharmaceuticals, Inc. : Optimer Reports Second Quarter 2013 Financial Results
PR
Optimer Pharmaceuticals, Inc. : OPTIMER PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Optimer Pharmaceuticals, Inc. Following Announcement of Proposed Sale of Company to Cubist Pharmaceuticals, Inc.
BU
Optimer Pharmaceuticals, Inc. : Finkelstein Thompson LLP Announces Investigation of Optimer Pharmaceuticals, Inc. Buyout
BU
Optimer Pharmaceuticals, Inc. : Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Optimer Pharmaceuticals Proposed Acquisition by Cubist Pharmaceuticals, Inc.
BU
Optimer Pharmaceuticals, Inc. : Cubist Pharmaceuticals to Acquire Optimer Pharmaceuticals
BU
Optimer Pharmaceuticals, Inc. : Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2013 Financial Results
PR
Optimer Pharmaceuticals, Inc. : Today's Technical View: Inovio Pharma, Sequenom, Onyx Pharma, and Optimer Pharma
PR
Optimer Pharmaceuticals, Inc. : Today's Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
PR
Optimer Pharmaceuticals, Inc. : Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
PR
Optimer Pharmaceuticals, Inc. : Optimer Reports First Quarter 2013 Financial Results
PR
Optimer Pharmaceuticals, Inc. : Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
PR
Optimer Pharmaceuticals, Inc. : DIFICID® (fidaxomicin) Tablets Approved in Australia
PR
Optimer Pharmaceuticals, Inc. : Pre-Market Analysis on Life Technologies, Quest Diagnostics, Brookdale Senior Living, Antares Pharma, and Optimer Pharma
PR
Optimer Pharmaceuticals, Inc. : Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
Optimer Pharmaceuticals, Inc. : Before the Bell Scans of Affymax, Questcor Pharma, Gilead Sciences, Vertex Pharma, and Optimer Pharma
PR
Optimer Pharmaceuticals, Inc. : Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Optimer Pharmaceuticals, Inc.